PMC:6909918 / 26414-27455 JSONTXT

{"project":"2_test","denotations":[{"id":"31790382-31278474-69134748","span":{"begin":152,"end":153},"obj":"31278474"},{"id":"31790382-31278474-69134749","span":{"begin":394,"end":395},"obj":"31278474"},{"id":"31790382-29174481-69134750","span":{"begin":913,"end":914},"obj":"29174481"},{"id":"31790382-31278474-69134751","span":{"begin":915,"end":916},"obj":"31278474"},{"id":"31790382-25970050-69134752","span":{"begin":968,"end":969},"obj":"25970050"},{"id":"31790382-29215955-69134753","span":{"begin":992,"end":993},"obj":"29215955"}],"text":"A further and more recently published meta-analysis compared the efficacy and safety of regorafenib with fruquintinib in pretreated patients with mCRC [9]. The findings showed that fruquintinib showed no significant difference on OS compared with regorafenib, and there was a trend for superiority in PFS of fruquintinib compared with regorafenib, which did not reach statistical significance [9]. In the present study, there was no significant difference in PFS in the indirect comparison of fruquintinib and regorafenib. Also, there was no significant difference in OS in the indirect comparison of fruquintinib with regorafenib, of in PFS or OS in the indirect comparison between fruquintinib and regorafenib. Therefore, in the present meta-analysis, although the inclusion of four RCTs showed similar outcomes for regorafenib, and fruquintinib in patients with refractory mCRC to previous meta-analysis data [8,9], the addition of TAS-102 with the RECOURSE trial [5] and the TERRA trial [6] provided more comprehensive data and findings."}